Victor Sandor
Director/Board Member at MERUS N.V.
Net worth: 261 969 $ as of 31/03/2024
Profile
Victor Sandor is an Independent Non-Executive Director at Merus NV, ADC Therapeutics SA, Prelude Therapeutics, Inc., Kymera Therapeutics, Inc., and Istari Oncology, Inc. He previously worked as the SVP-Global Clinical Development at Incyte Corp., Chief Medical Officer at Array BioPharma, Inc., and Chief Medical Officer-Oncology & VP at Biogen Idec, Inc. He holds a doctorate degree from McGill University.
Known holdings in public companies
Company | Date | Number of shares | Valuation | Valuation date |
---|---|---|---|---|
ADC THERAPEUTICS LTD
0.07% | 01/02/2024 | 58,345 ( 0.07% ) | 261 969 $ | 31/03/2024 |
MERUS N.V.
-.--% | 08/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 | |
15/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Victor Sandor active positions
Companies | Position | Start |
---|---|---|
MERUS N.V. | Director/Board Member | 12/06/2019 |
ADC THERAPEUTICS SA | Director/Board Member | 27/04/2020 |
PRELUDE THERAPEUTICS INCORPORATED | Director/Board Member | 01/05/2020 |
KYMERA THERAPEUTICS, INC. | Director/Board Member | 03/11/2022 |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Director/Board Member | 01/07/2019 |
Former positions of Victor Sandor
Companies | Position | End |
---|---|---|
INCYTE CORPORATION | Chief Tech/Sci/R&D Officer | 01/09/2019 |
ARRAY TECHNOLOGIES, INC. | Chief Tech/Sci/R&D Officer | 01/08/2019 |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Corporate Officer/Principal | 01/09/2014 |
Training of Victor Sandor
McGill University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 5 |
---|---|
INCYTE CORPORATION | Health Technology |
MERUS N.V. | Health Technology |
ADC THERAPEUTICS SA | Health Technology |
PRELUDE THERAPEUTICS INCORPORATED | Health Technology |
KYMERA THERAPEUTICS, INC. | Health Technology |
Private companies | 3 |
---|---|
Array BioPharma, Inc.
Array BioPharma, Inc. Pharmaceuticals: MajorHealth Technology Array BioPharma, Inc. is a biopharmaceutical company. Its focus is on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company's products are BRAFTOVI and MEKTOVI. Its portfolio includes Binimetinib, Selumetinib, Encorafenib, Filanesib, Ipatasertib, Varltinib, Danoprevir, ARRY-797, Larotrectinib, Tucatinib, ARRY-382, Motolimod, Prexasertib, GDC-0575, LOXO-292, LOXO-195, and AK-1830. The company was founded by Kevin Koch, Anthony D. Piscopio, K. C. Nicolaou, and David L. Snitman in 1998 and is headquartered in Boulder, CO. | Health Technology |
Biogen Idec, Inc. (North Carolina)
Biogen Idec, Inc. (North Carolina) Pharmaceuticals: MajorHealth Technology Part of Biogen, Inc., Biogen Idec, Inc. (North Carolina) is a pharmaceutical company based in Durham, NC. The private company develops pharmaceutical products. Michel Pericles Vounatsos has been the CEO of the company since 2016. | Health Technology |
Istari Oncology, Inc.
Istari Oncology, Inc. BiotechnologyHealth Technology Istari Oncology, Inc. operates as a clinical-stage biotechnology company. It focuses on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors. Its core technology assets are PVS-RIPO, a prototypic oncolytic recombinant polio virus vaccine, and a series of antibody-drug conjugates comprising antibodies or antibody fragments to a variety of oncology targets. The company was founded by Darell D. Bigner and Matthias Gromeier in 2016 and is headquartered in Research Triangle Park, NC. | Health Technology |
- Stock Market
- Insiders
- Victor Sandor